Healthcare Sales & Marketing Network News: multiple myeloma

Searching News Database: multiple myeloma

HSMN NewsFeed - 26 Nov 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2024
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2023
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Nov 2022
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Feb 2022
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
Diagnostics Mergers & Acquisitions

HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 25 Nov 2021
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Feb 2021
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel

HSMN NewsFeed - 18 Nov 2020
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Oct 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Biopharmaceuticals Licensing Acquisitions

HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
Devices Oncology

HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Aug 2020
Phosplatin Therapeutics Completes $18.4 Million Private Financing Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 May 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 May 2020
Ichnos Sciences Appoints David Lubner To Board Of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Feb 2020
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2019
Oncopeptides Appoints Joseph Horvat as President North America
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory

HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions

HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Nov 2018
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 8 Nov 2018
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 20 Jun 2018
Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures
Devices Interventional Radiology Orthopaedic FDA

HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2018
Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jan 2018
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin(R) (plitidepsin) With Megapharm in Israel
Biopharmaceuticals Oncology Licensing Distribution

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Sep 2017
NCCN Guidelines to Include Categories of Preference
Biopharmaceuticals Devices Oncology

HSMN NewsFeed - 25 Jul 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 12 Apr 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Mar 2017
Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Nov 2016
Oncolytics Biotech(R) Inc. Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Nov 2016
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
Diagnostics Oncology Mergers & Acquisitions

HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Jul 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Jul 2016
Bach Pharma Appoints Kelly Blackburn as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 May 2016
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
Biopharmaceuticals Ophthalmology Acquisitions

HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Feb 2016
PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for APLIDIN(R) (plitidepsin) Covering Several Asian Countries
Biopharmaceuticals Oncology Licensing Distribution

HSMN NewsFeed - 28 Jan 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Jan 2016
Dr. Rolf Muller Appointed as New CEO of BioFluidica, Inc.
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Launches with $73 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 7 Jan 2016
BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome
Diagnostics Ophthalmology

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Dec 2015
European Commission Approves Amgen's IMLYGIC(TM) (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Dec 2015
Kesios Therapeutics Raises £19 Million in Series A Financing
Biopharmaceuticals Oncology Personnel Venture Capital

HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel

HSMN NewsFeed - 27 Jul 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jun 2015
Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Mar 2015
Janssen Acquires XO1 Limited
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Feb 2015
BioLight Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence with the CellDetect(R) Non-Invasive Test
Devices Diagnostics Oncology

HSMN NewsFeed - 18 Sep 2014
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Aug 2014
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals

HSMN NewsFeed - 29 May 2014
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2014
Janssen Announces New Group Targeting Unmet Global Health Needs
Biopharmaceuticals

HSMN NewsFeed - 15 Jan 2014
AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Dec 2013
Senesco Announces Letter of Intent to Merge with Fabrus
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals

HSMN NewsFeed - 21 Nov 2013
Array BioPharma Announces Management Team Change
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals

HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Sep 2013
Lipella Pharmaceuticals Inc. Names David Lucchino to Board of Directors
Biopharmaceuticals Drug Delivery Urology Personnel

HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Jul 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jun 2013
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 24 Apr 2013
Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Apr 2013
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 13 Feb 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
Biopharmaceuticals Devices Oncology

HSMN NewsFeed - 20 Nov 2012
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Biopharmaceuticals Personalized Medicine Oncology

HSMN NewsFeed - 11 Oct 2012
Zyngenia, Inc. Expands Its Board of Directors with Leading Life Sciences Business Executives Christian Itin and Jason Rhodes
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Oct 2012
Gliknik Raises $4.9 Million In Series B Financing Led By Baxter Ventures
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Sep 2012
Cialis(R) (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
Biopharmaceuticals Urology Regulatory

HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 23 Aug 2012
St. Jude Medical Announces Death of Board Member Thomas H. Garrett
Devices Personnel

HSMN NewsFeed - 14 Aug 2012
Pharmacyclics(R) Appoints Joshua T. Brumm Executive Vice President of Finance
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals

HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 26 Apr 2012
Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Apr 2012
Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Feb 2012
New Study Evaluates Cialis(R) in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology

HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Oct 2011
Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Aug 2011
Researchers Find RapidArc(R) Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
Devices Oncology

HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
Oncology

HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2011
FDA Grants Orphan Drug Designation for XTL's rHuEPO Treatment for Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Mar 2011
XTL Biopharmaceuticals to Acquire MinoGuard Ltd.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 21 Mar 2011
Kyphon(R) Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
Devices Orthopaedic Neurosurgery Oncology

HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Feb 2011
Cellerant Therapeutics Announces Key Additions to Sr. Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jan 2011
Ligand Acquires CyDex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Jan 2011
Multiple Myeloma Research Foundation (MMRF) Saddened by Loss of Dear Friend and Former Board Member Bob DeBaun
Oncology Personnel

HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2010
New Multiple Myeloma Treatment Guidelines for Patients Available from NCCN
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Oct 2010
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Sep 2010
Chronix Biomedical Announces Completion of Series E Financing
Diagnostics Oncology Venture Capital

HSMN NewsFeed - 8 Sep 2010
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Aug 2010
ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Aug 2010
Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jul 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Jul 2010
Calithera Biosciences Closes $40 Million in Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Mar 2010
Newly Published Data Shows Chronix Biomedical's Serum DNA Assays Can Detect Early-Stage Breast Cancer
Diagnostics Oncology

HSMN NewsFeed - 1 Mar 2010
AEterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2010
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and John van Duzer VP Chemistry and Manufacturing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology

HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Dec 2009
ImmunoCellular Therapeutics Enters into Option Agreement with The University of Texas M. D. Anderson Cancer Center for a Novel Cancer Stem Cell Therapy
Regenerative Medicine Oncology

HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 12 Oct 2009
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Aug 2009
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
Biopharmaceuticals Oncology Litigation

HSMN NewsFeed - 19 Aug 2009
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Biopharmaceuticals

HSMN NewsFeed - 7 Aug 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 4 Aug 2009
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Biopharmaceuticals Licensing Litigation

HSMN NewsFeed - 27 Jul 2009
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Biopharmaceuticals

HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals

HSMN NewsFeed - 22 Jun 2009
Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 29 Apr 2009
Cougar Biotechnology Initiates Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy-Nave Castration-Resistant Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Feb 2009
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Feb 2009
Enzon Discontinues Further Development of rhMBL
Biopharmaceuticals

HSMN NewsFeed - 30 Jan 2009
REVLIMID Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Oct 2008
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Sep 2008
Proteolix Raises $79 Million in Series C Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Jul 2008
Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2008
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Jun 2008
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Jun 2008
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2008
Bristol-Myers Squibb to Acquire Kosan Biosciences
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 May 2008
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals

HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 May 2008
Proteolix Appoints Thomas Kassberg Executive Vice President of Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Apr 2008
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2008
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Apr 2008
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Biopharmaceuticals

HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Feb 2008
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jan 2008
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jan 2008
Gloucester Pharmaceuticals Announces New Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jan 2008
Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Jan 2008
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2008
Callisto Pharmaceuticals Amends and Restates Atiprimod License Agreement with Genzyme
Biopharmaceuticals Licensing

HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Nov 2007
Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 12 Nov 2007
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Oct 2007
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2007
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 15 Oct 2007
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Oct 2007
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 24 Sep 2007
Progen Announces PI-88 Phase 2 Lung Cancer Results
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
Biopharmaceuticals Licensing Oncology

HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2007
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Biopharmaceuticals

HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Aug 2007
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Aug 2007
Immunomedics Appoints Edward T. Wolynic to Board Of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jul 2007
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jun 2007
Seattle Genetics Adds Industry Veterans John P. McLaughlin and Daniel G. Welch to its Board of Directors and Promotes Eric Dobmeier to Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Jun 2007
Aquinox Pharmaceuticals completes US $ 14.5 million Series A financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Jun 2007
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jun 2007
Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversion and Related Claims
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jun 2007
INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in Previously Treated Patients With Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 May 2007
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Apr 2007
INVEGA(R) Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Mar 2007
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
Biopharmaceuticals

HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Mar 2007
Seattle Genetics Appoints Dr. Tom Reynolds Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Feb 2007
Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Jan 2007
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2007
Proteolix Elects Dr. Michael Kauffman Chairman of the Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Jan 2007
NCCN Updates Multiple Myeloma Guidelines
Oncology

HSMN NewsFeed - 8 Jan 2007
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 8 Jan 2007
Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
Biopharmaceuticals Licensing

HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2007
Avalon Pharmaceuticals Names Clinical Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jan 2007
Kosan Appoints Jane Green as Vice President, Corporate Communications
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Dec 2006
Dr. Geoffrey Henson to Join Callisto Pharmaceuticals
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Dec 2006
Celgene Notified of ANDA Filing for Thalidomide
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 21 Dec 2006
Callisto Pharmaceuticals Files Suit Against Tapestry Pharmaceuticals for Breach of Confidential Disclosure Agreement
Biopharmaceuticals Litigation

HSMN NewsFeed - 20 Dec 2006
Kosan Announces License of Motilin Agonist Program to Pfizer
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
Celgene Notified of ANDA Filing for Thalidomide
Biopharmaceuticals Generics FDA Litigation

HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Dec 2006
INNOVIVE Pharmaceuticals Acquires Exclusive North American Rights to Tamibarotene, a Treatment for Acute Promyelocytic Leukemia; Company to Initiate Pivotal Study in 2007
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Nov 2006
Genzyme Completes Tender Offer for Outstanding Shares of AnorMED
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Oct 2006
Kosan Appoints Robert De Jager as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2006
Genzyme and AnorMED Reach Agreement on Acquisition
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 10 Oct 2006
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Oct 2006
Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice President of Clinical Development - Oncology
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Sep 2006
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy

HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Sep 2006
Hyam I. Levitsky, MD, Joins Antigenics' Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jul 2006
ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics
Biopharmaceuticals Licensing

HSMN NewsFeed - 10 Jul 2006
AnorMED completes enrollment in Phase III trial for MOZOBIL in stem cell transplant in multiple myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 29 Jun 2006
The International Myeloma Foundation Says REVLIMID(R) Approval for Multiple Myeloma Can Be Life-Changing for Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2006
Nereus Pharmaceuticals Appoints Dr. Charles White as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Jun 2006
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2006
Proteolix Closes $45 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 May 2006
Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2006
AnorMED President and CEO Michael Abrams steps down
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 May 2006
Pharmion Appoints Andrew Allen as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Biopharmaceuticals Oncology Distribution

Return to NewsFeed

Additional items found! 298

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 298 additional stories matching:
multiple myeloma
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.